'Altuviiio,' a once-weekly administered hemophilia A new drug, has been designated as Korea’s Orphan Drug.

The Ministry of Food and Drug Safety (MFDS) announced this in a recent posting.

Sanofi-Aventis Korea’s Altuviiio (efanesoctocog alfa) is a first-in-class high sustained factor (HSF) therapy for hemophilia A. With once-weekly treatment, Altuviio keeps hemophilia factor activity levels at over 40%, and helps provide patients with a near to normal life.

Altuviiio provides bleed protection through a once-weekly treatment and delivers the longest sustained protection as a factor-based therapy, except for non-factor agents.

When designated as Or